<DOC>
	<DOCNO>NCT00077714</DOCNO>
	<brief_summary>The purpose trial determine paliperidone ER effective treatment adult schizophrenia .</brief_summary>
	<brief_title>Trial Evaluating Efficacy Safety 2 Fixed Doses Paliperidone Extended-Release ( ER ) Tablets Treatment Adult Patients With Schizophrenia</brief_title>
	<detailed_description>Paliperidone develop new therapeutic agent treatment schizophrenia . The extended-release ( ER ) formulation paliperidone develop deliver paliperidone relatively constant rate 24-hour period improve tolerability profile decrease potential orthostatic hypotension . This study design evaluate efficacy , safety tolerability 2 fix dosage paliperidone ER compare placebo adult patient schizophrenia . This multicenter , double-blind ( neither patient physician know placebo drug give dose ) , randomize ( patient assign different treatment group base solely chance ) , placebo- active-controlled , parallel-group , dose-response study . Patients randomize 1 4 treatment group receive oral dosage paliperidone ER 6 mg 12 mg , olanzapine 10 mg , placebo daily 6-week period . The study include screening period 5 day , follow 6-week double-blind treatment phase . Following double-blind treatment phase , eligible patient ( complete 6-week double-blind phase discontinue due lack efficacy minimum 21 day ) may enter 52-week open-label extension phase paliperidone ER monotherapy . While patient hospitalize , efficacy assess twice first week end second week , patient discharge hospital , return efficacy safety assessment perform weekly basis end 6-week double-blind phase . Efficacy evaluate throughout 6-week double-blind phase completion Positive Negative Syndrome Scale ( PANSS ) , Clinical Global Impression Scale - Severity ( CGI-S ) , Personal Social Performance Scale ( PSP ) , Schizophrenia Quality Life Scale , Revision 4 ( SQLS-R4 ) , Sleep Visual Analog Scale ( VAS ) . The efficacy response measure change baseline score end double-blind phase PANSS , PSP , CGI-S , SQLS-R4 , Sleep VAS . Safety monitor throughout study include assessment incidence adverse event ; measurement extrapyramidal symptom use 3 rating scale ( Abnormal Involuntary Movement Scale [ AIMS ] , Barnes Akathisia Rating Scale [ BARS ] , Simpson-Angus Rating Scale [ SAS ] ) ; measurement vital sign ( lay stand blood pressure , pulse , temperature ) ; electrocardiogram ; clinical laboratory test . Double-blind : 6 mg 12 mg fix dose paliperidone ER , olanzapine 10 mg match placebo take orally daily 6 week . Open-label extension : start paliperidone ER 9 mg take orally daily ; maintain flexible dosage paliperidone ER ( 3 , 6 , 9 , 12 mg/day ) 52 week .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Doubleblind phase : DSMIV diagnosis schizophrenia least 1 year experience acute episode , total PANSS score screen 70 120 agree voluntary hospitalization minimum 14 day . Openlabel phase : must complete 6 week doubleblind treatment complete least 21 day treatment discontinue due lack efficacy . DSMIV axis I diagnosis schizophrenia DSMIV diagnosis substance dependence within 6 month prior screen evaluation ( nicotine caffeine dependence exclusionary ) history neuroleptic malignant syndrome ( NMS ) history severe preexist gastrointestinal narrowing ( pathologic iatrogenic ) previous history lack response risperidone acutely psychotic significant risk suicidal violent behavior .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone</keyword>
</DOC>